Condition: Advanced Solid Tumor With Lung and/or Liver Involvement · Sponsor: BrYet US, Inc.
This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).
This description comes directly from the study's public registry record.
Amanda Jubb, Clinical Project Manager, Southern Star Research · +61 (0)2 9011 6266 · ajubb@southernstarresearch.com
Matt Wagener, VP Clinical Development Operations, BrYet · matt.wagener@bryetpharma.com
Always discuss trial participation with your own doctor first.
| Southside Cancer Care Centre | Miranda, New South Wales, Australia | — |
| Illawarra Cancer Care Center, Wollongong Hospital | Wollongong, New South Wales, Australia | — |
| Sunshine Coast Haematology and Oncology Clinic | Buderim, Queensland, Australia | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07723482